Abstract: The present invention relates to a novel formulation comprising a benzimidazole derivative. The formulation for oral administration comprising a compound of Formula 1 according to the present invention or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose, exhibits an excellent storage stability and has an effect on preventing a phenomenon of decline in dissolution rate, thus being usefully used as a formulation for oral administration.

Abstract: The present invention relates to a novel formulation comprising a benzimidazole derivative. The formulation for oral administration comprising a compound of Formula 1 according to the present invention or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose, exhibits an excellent storage stability and has an effect on preventing a phenomenon of decline in dissolution rate, thus being usefully used as a formulation for oral administration.

Abstract: The present invention relates to a novel formulation comprising a benzimidazole derivative. The formulation for oral administration comprising a compound of Formula 1 according to the present invention or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose, exhibits an excellent storage stability and has an effect on preventing a phenomenon of decline in dissolution rate, thus being usefully used as a formulation for oral administration.

Abstract: The present invention relates to a gastric-retention type sustained-release formulation of metformin as an insulin-independent diabetic agent, and a preparation method thereof. More specifically, the present invention relates to a gastric-retention type sustained-release formulation, which can effectively control drug release even with a small amount of a polymer by forming a sustained-release granulated material, which comprises granules containing metformin or a pharmaceutically acceptable salt thereof and a swellable polymer, and a water-insoluble coated on the surface of the granules; and also can allow a tablet containing the drug to swell rapidly at an early stage by formulating via mixing of a superdisintegrant, which is capable of controlling the speed of gelation forming hydrogels, with the granulated material; and a preparation method thereof.

Abstract: The present invention relates to a solifenacin preparation containing solifenacin or a pharmaceutically acceptable salt thereof, an antioxidant, and a binder, which is manufactured via direct compression. Compared to the preparations manufactured via conventional wet granulation process, the preparation of the present invention can be manufactured by a simplified process such as direct compression, and has improved content uniformity, mixing degree, etc., even when the preparation is manufactured by high speed tableting.

Abstract: The present invention relates to a solifenacin preparation containing solifenacin or a pharmaceutically acceptable salt thereof, an antioxidant, and a binder, which is manufactured via direct compression. Compared to the preparations manufactured via conventional wet granulation process, the preparation of the present invention can be manufactured by a simplified process such as direct compression, and has improved content uniformity, mixing degree, etc., even when the preparation is manufactured by high speed tableting.

Abstract: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.

Abstract: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.

Abstract: The present invention relates to a novel diaryl 1,2,4-triazole derivative of the following formula (1) as a highly selective cyclooxygenase-2 inhibitor, wherein R1, R2, R3, R4, R5, W and A is as defined in this specification.

Abstract: The present invention relates to a novel diaryl 1,2,4-triazole derivative of the following formula 1 as a highly selective cyclooxygenase-2 inhibitor: Wherein, R1, R2, R3, R4, R5, W and A is as defined in this specification.

Abstract: A 1,2,4-Triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.

Abstract: The present invention relates to a novel diaryl 1,2,4-triazole derivative of the following formula 1 as a highly selective cyclooxygenase-2 inhibitor: Wherein, R1, R2, R3, R4, R5, W and A is as defined in this specification.

Abstract: The present invention relates to a novel diaryl 1,2,4-triazole derivative of the following formula (1) as a highly selective cyclooxygenase-2 inhibitor, wherein R1, R2, R3, R4, R5, W and A is as defined in this specification.